Search research articles
Contact Us
Filters
Showing results (51-60 of 57) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 57 results.
La Clinica Terapeutica
|
November 23, 2023
Omics sciences and precision medicine in Urothelial Carcinoma
M C Medori, C Micheletti, G Madeo, et al.
ESMO Open
|
April 5, 2021
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
F Schettini, B Conte, G Buono, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2025
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study
L Provenzano, M V Dieci, G Curigliano, et al.
Breast (Edinburgh, Scotland)
|
July 17, 2017
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
M E Cazzaniga, M Airoldi, V Arcangeli, et al.
Scientific Reports
|
July 28, 2023
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients
B Trevisan, F F Pepe, I Vallini, et al.
Breast (Edinburgh, Scotland)
|
August 31, 2019
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
M E Cazzaniga, G Pinotti, E Montagna, et al.
Breast Cancer Research and Treatment
|
September 21, 2021
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
M E Cazzaniga, I Vallini, E Montagna, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 57) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 57 results.
La Clinica Terapeutica
|
November 23, 2023
Omics sciences and precision medicine in Urothelial Carcinoma
M C Medori, C Micheletti, G Madeo, et al.
ESMO Open
|
April 5, 2021
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
F Schettini, B Conte, G Buono, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2025
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study
L Provenzano, M V Dieci, G Curigliano, et al.
Breast (Edinburgh, Scotland)
|
July 17, 2017
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
M E Cazzaniga, M Airoldi, V Arcangeli, et al.
Scientific Reports
|
July 28, 2023
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients
B Trevisan, F F Pepe, I Vallini, et al.
Breast (Edinburgh, Scotland)
|
August 31, 2019
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
M E Cazzaniga, G Pinotti, E Montagna, et al.
Breast Cancer Research and Treatment
|
September 21, 2021
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
M E Cazzaniga, I Vallini, E Montagna, et al.
Page
of 6